Literature DB >> 20735724

Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry.

P Prandoni, J Trujillo-Santos, E Sanchez-Cantalejo, F Dalla Valle, C Piovella, R Pesavento, J A Nieto Rodríguez, M Monreal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20735724     DOI： 10.1111/j.1538-7836.2010.04039.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  7 in total

Review 1.  New anticoagulants for the treatment of venous thromboembolism.

Authors:  Caio Julio Cesar Dos Santos Fernandes; José Leonidas Alves Júnior; Francisca Gavilanes; Luis Felipe Prada; Luciana Kato Morinaga; Rogerio Souza
Journal:  J Bras Pneumol       Date:  2016-04       Impact factor: 2.624

2.  Inadvertent Overdose of Low-Molecular-Weight Heparin in an Elderly Patient with Deep Vein Thrombosis and Acute Kidney Injury.

Authors:  Abdullah S Al Saleh; David Anderson
Journal:  Can J Hosp Pharm       Date:  2016-08-31

3.  Prevention and treatment of venous thromboembolism in patients with cancer.

Authors:  Kerstin Hogg; Marc Carrier
Journal:  Ther Adv Hematol       Date:  2012-02

Review 4.  Atrial Fibrillation and Stroke Risk in Patients With Cancer: A Primer for Oncologists.

Authors:  Marc Sorigue; Milos D Miljkovic
Journal:  J Oncol Pract       Date:  2019-12       Impact factor: 3.840

Review 5.  Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants.

Authors:  Vincent Geldhof; Christophe Vandenbriele; Peter Verhamme; Thomas Vanassche
Journal:  Thromb J       Date:  2014-10-13

Review 6.  Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.

Authors:  A T Cohen; M Hamilton; S A Mitchell; H Phatak; X Liu; A Bird; D Tushabe; S Batson
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

7.  Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.

Authors:  Tereza Lanitis; Robert Leipold; Melissa Hamilton; Dale Rublee; Peter Quon; Chantelle Browne; Alexander T Cohen
Journal:  BMC Health Serv Res       Date:  2017-01-23       Impact factor: 2.655
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.